Pinaverium bromide: Difference between revisions

{{Short description|Chemical compound}}

| Verifiedfields = changed

| verifiedrevid = 448202349

| IUPAC_name = 4-[(2-Bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium bromide

| image = pinaverium bromide.svg

| routes_of_administration =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 53251-94-8

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 7SCF54H12J

| PubChem = 40703

| DrugBank = DBSALT001130

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 37181

| smiles = CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)Cc4cc(c(cc4Br)OC)OC)C.[Br-]

| StdInChI_Ref = {{stdinchicite|changed|chemspider}}

| StdInChI = 1S/C26H41BrNO4.BrH/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27;/h15,17,19,21-22H,5-14,16,18H2,1-4H3;1H/q+1;/p-1

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| StdInChIKey = IKGXLCMLVINENI-UHFFFAOYSA-M

| C=26 | H=41 | Br=2 | N=1 | O=4

'''Pinaverium bromide''' ([[International Nonproprietary Name|INN]]) is a medication used for [[functional gastrointestinal disorder]]s. It belongs to a drug group called [[antispasmodic]]s and acts as a [[calcium channel blocker]] in helping to restore the normal contraction process of the bowel. It is most effective when taken for a full course of treatment and is not designed for immediate symptom relief or sporadic, intermittent use.<ref>{{cite book | vauthors = | chapter = Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines [Internet]. | title = CADTH Rapid Response Reports | location = Ottawa (ON) | publisher = Canadian Agency for Drugs and Technologies in Health | date = November 2015 | pmid = 26985535 | chapter-url = https://www.ncbi.nlm.nih.gov/books/NBK350043/ }}</ref>

Pinaverium bromide was first registered in 1975 by [[Solvay_S.A.|Solvay Pharmaceuticals]] (now a division of [[Abbott Laboratories]]), and marketed globally using the brand names '''Dicetel''' and '''Eldicet'''. Generic pinaverium is available in South Korea under a trade name of '''Disten'''<ref>{{cite web | url = http://www.kmle.co.kr/viewDrug.php?m=%B6%F3%BD%C4&inx=26702&c=afdf17b8b3cde357bf3163dd78dbc00f | work = KMLE | title = Drug/Drug Information: Disten Tablet | language = ko | access-date = 2016-03-07 | archive-date = 2018-09-20 | archive-url = https://web.archive.org/web/20180920111710/http://www.kmle.co.kr/viewDrug.php?m=%B6%F3%BD%C4&inx=26702&c=afdf17b8b3cde357bf3163dd78dbc00f | url-status = dead }}</ref> and in Argentina as '''Nulite'''.<ref>{{Cite web | url=http://www.labdominguez.com.ar/es/productos/28-nulite | title=NULITE | work=Laboratorio Dominguez | access-date=2017-07-03 | archive-date=2019-08-24 | archive-url=https://web.archive.org/web/20190824084406/http://www.labdominguez.com.ar/es/productos/28-nulite | url-status=dead }}</ref>

==Indications==

It is indicated for the treatment and relief of symptoms associated with [[irritable bowel syndrome]] (IBS) including abdominal pain, bowel disturbances and intestinal discomfort; and treatment of symptoms related to functional disorders of biliary tract.<ref>{{Cite book|author=Abbott Laboratories |title=Dicetel Product Insert/Information Malaysia| date=Feb 2012 }}</ref>

==References==

{{Reflist}}

[[Category:Drugs developed by AbbVie]]

[[Category:Methoxy compounds]]